Literature DB >> 1458563

Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

D de Vos1, P H Slee, D Stevenson, R J Briggs.   

Abstract

In breast cancer patients discontinuing chronic tamoxifen therapy, the serum elimination of metabolites X, Y and E paralleled that of tamoxifen, whereas that of metabolite Z did not. The serum elimination of tamoxifen and metabolites X and B was increased by amino-glutethimide treatment, whereas that of metabolites Z, Y, and E was not.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1458563     DOI： 10.1007/bf00695998

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  18 in total

1.  Determination of tamoxifen and five metabolites in plasma.

Authors:  D Stevenson; R J Briggs; D J Chapman; D De Vos
Journal:  J Pharm Biomed Anal       Date:  1988       Impact factor: 3.935

2.  Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

Authors:  E A Lien; G Anker; P E Lønning; E Solheim; P M Ueland
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

Review 3.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

4.  Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma.

Authors:  Y Golander; L A Sternson
Journal:  J Chromatogr       Date:  1980-01-11

5.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  S Lundgren; P E Lønning; A Aakvaag; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  A bioavailability study of two preparations of tamoxifen after single doses.

Authors:  D Stevenson; R Briggs; G P Mould
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

Review 7.  Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

Review 8.  Potential role of tamoxifen in prevention of breast cancer.

Authors:  S G Nayfield; J E Karp; L G Ford; F A Dorr; B S Kramer
Journal:  J Natl Cancer Inst       Date:  1991-10-16       Impact factor: 13.506

9.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Kinetics of tamoxifen inhibition of aryl hydrocarbon hydroxylase activity of intestinal and hepatic microsomes from male rats.

Authors:  W A Al-Turk; S J Stohs
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-01
View more
  4 in total

Review 1.  Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Authors:  Sarah Mikelman; Natalie Mardirossian; Margaret E Gnegy
Journal:  J Chem Neuroanat       Date:  2016-08-30       Impact factor: 3.052

2.  Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.

Authors:  Kristin Dickschen; Stefan Willmann; Kirstin Thelen; Jörg Lippert; Georg Hempel; Thomas Eissing
Journal:  Front Pharmacol       Date:  2012-05-21       Impact factor: 5.810

3.  The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.

Authors:  S R Johnston; S Riddler; B P Haynes; R A'Hern; I E Smith; M Jarman; M Dowsett
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Tamoxifen in horses: pharmacokinetics and safety study.

Authors:  Gonzalo Gajardo; Rodrigo López-Muñoz; Anita Plaza; Benjamin Uberti; José Sarmiento; Gabriel Morán; Claudio Henríquez
Journal:  Ir Vet J       Date:  2019-06-20       Impact factor: 2.146
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.